The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; MSD Oncology; Roche/Genentech; Takeda
Consulting or Advisory Role - AstraZeneca Spain; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Roche/Genentech; Takeda
Research Funding - AstraZeneca Spain (Inst)
 
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; MSD; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; MSD; Pfizer
An open-label, multicenter, phase 2 study of the safety and efficacy of navtemadlin (KRT-232) in patients with TP53 wild-type relapsed/refractory small cell lung cancer.
 
Afshin Dowlati
Consulting or Advisory Role - Abbvie/Stemcentrx; AstraZeneca; Bayer; Bristol-Myers Squibb; G1 Therapeutics; Ipsen; Merck; Takeda
Research Funding - Abbvie/Stemcentrx (Inst); Amgen (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Lilly/ImClone (Inst); Mirati Therapeutics (Inst); Regeneron (Inst); Seagen (Inst); Symphogen (Inst); Takeda (Inst); Tesaro (Inst); United Therapeutics (Inst)
 
Oscar Juan-Vidal
No Relationships to Disclose
 
Sandrine Hiret
Consulting or Advisory Role - AstraZeneca; BMS; Roche; Takeda
Travel, Accommodations, Expenses - Roche
 
Achim Rittmeyer
Consulting or Advisory Role - AbbVie; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Bristol-Myers Squibb; Lilly; MSD; Novartis; Roche/Genentech
 
Shawgi Sukumaran
No Relationships to Disclose
 
David Vicente Baz
No Relationships to Disclose
 
Jorge Arturo Rios-Perez
No Relationships to Disclose
 
Eric Michael Harris
Honoraria - Bristol-Myers Squibb; Gilead Sciences; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Novartis
Speakers' Bureau - Bristol-Myers Squibb (Mexico); Gilead Sciences; Novartis
Research Funding - Apollomics; AstraZeneca; BeiGene; BioAtla; Calithera Biosciences; Genentech; Mirati Therapeutics; Odonate Therapeutics; Roche; Taiho Oncology; Takeda
 
Steven L. McCune
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; Roche/Genentech
Other Relationship - Roche (Inst)
 
Melissa Lynne Johnson
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Axelia Oncology (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); EcoR1 Capital (Inst); Editas Medicine (Inst); Eisai (Inst); EMD Serono (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); IDEAYA Biosciences (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Oncorus (Inst); Regeneron (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Turning Point Therapeutics (Inst); WindMIL (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Amgen (Inst); Apexigen (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Artios (Inst); AstraZeneca (Inst); Atreca (Inst); BeiGene (Inst); BerGenBio (Inst); BioAtla (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Calithera Biosciences (Inst); Carisma Therapeutics (Inst); Checkpoint Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curis (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Dracen (Inst); Dynavax Technologies (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Exelixis (Inst); Fate Therapeutics (Inst); Genentech/Roche (Inst); Genmab (Inst); Genocea Biosciences (Inst); GlaxoSmithKline (Inst); Gritstone Bio (Inst); Guardant Health (Inst); Harpoon (Inst); Helsinn Healthcare (Inst); Hengrui Pharmaceutical (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); IGM Biosciences (Inst); Immunocore (Inst); IMPAC Medical Systems (Inst); Incyte (Inst); Janssen (Inst); Jounce Therapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Lilly (Inst); Loxo (Inst); Lycera (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); NeoImmuneTech (Inst); Neovia Oncology (Inst); Novartis (Inst); Numab (Inst); Nuvalent, Inc. (Inst); OncoMed (Inst); Palleon Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Rain Therapeutics (Inst); RasCal (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Ribon Therapeutics (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Seven and Eight Biopharmaceuticals (Inst); Shattuck Labs (Inst); Silicon Therapeutics (Inst); Stem CentRx (Inst); Syndax (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); TCR2 Therapeutics (Inst); Tempest Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tmunity Therapeutics, Inc. (Inst); Turning Point Therapeutics (Inst); University of Michigan (Inst); Vyriad (Inst); WindMIL (Inst); Y-mAbs Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Genentech; Incyte; Merck; Pfizer; Sanofi
 
Brandon Croft
Employment - Kartos Therapeutics; Roche/Genentech
Stock and Other Ownership Interests - Kartos Therapeutics; Roche/Genentech; Telios
 
Jesse S. McGreivy
Employment - Kartos Therapeutics
Leadership - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics
Travel, Accommodations, Expenses - Kartos Therapeutics
 
Wayne P. Rothbaum
Leadership - Iovance Biotherapeutics
Stock and Other Ownership Interests - Acerta Pharma/AstraZeneca (Inst); Kartos Therapeutics (Inst); Telios (Inst)
Patents, Royalties, Other Intellectual Property - Telios Pharma and Kartos Therapeutics
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Kartos Therapeutics
(OPTIONAL) Uncompensated Relationships - Kartos Therapeutics (Inst); Telios (Inst)
 
Javier de Castro Carpeño
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; GlaxoSmithKline; Janssen Oncology; Lilly; Merck Sharp and Dohme; Pfizer; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - AstraZeneca Spain; Merck Sharp & Dohme; Roche